Search Results
Your search for ,OUr matches 10642 pages
Showing 6801 - 6850New NCCN Patient Resources Assist Decision-Making for Patients With Stomach Cancer
According to the American Cancer Society, it is estimated that more than 26,000 people will be diagnosed with stomach cancer in the United States this year, with nearly 1 million new cases diagnosed worldwide each year, according to the World Health Organization. Because there are no early symptoms ...
Using Pharmacogenetics to Predict Cancer Prognosis, Response to Treatment, and Toxicity
Although clinical trials are helpful in determining the effectiveness of a specific drug across a patient population, they are not as reliable at pinpointing how well a particular patient will respond to the drug or dosing regimen or how the drug may impact the patient’s quality of life from...
Rise in Oropharyngeal Cancer Incidence in the UK Not Solely Driven by HPV
The rise in the incidence of oropharyngeal squamous cell carcinoma in the United Kingdom from 2002 to 2011 was not solely attributable to a rise in the incidence of human papillomavirus (HPV)-positive disease, according to a study published in Cancer Research,1 which reported that the proportion of ...
When Breath Becomes Air: Dr. Lucy Kalanithi Reflects on Dr. Paul Kalanithi’s Life and Writing
Perhaps more than any other book in recent memory, When Breath Becomes Air has struck a chord among readers, both inside the medical community and among the public, desiring an honest and philosophical consideration of death. The autobiographical account of Paul Kalanithi, MD, a physician diagnosed ...
Leave a Legacy of Hope
By including a planned gift to the Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for cancer patients years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: Your...
New Member Categories Provide Specialized Support to Cancer Care Team Members
As part of ASCO’s ongoing effort to fully support all members of the cancer care team, it recently created three new member categories: Advanced Practice Providers, Practice Administrators, and Patient Advocates (see sidebar). Originally part of the Affiliated Health Professionals member category, ...
ASCO Presents First-Ever ASCO Congressional Leadership Award to Representative Michael Burgess, MD
ASCO presented Representative Michael Burgess, MD (TX-26) with the Society’s first-ever ASCO Congressional Leadership Award to recognize his steadfast work to advance policies that support cancer research and treatment. This new, annual award honors a Member of Congress who is a dedicated champion ...
Precision Promise Clinical Trial Focuses on Precision Medicine, Collaboration, and Data-Sharing in Pancreatic Cancer
The Pancreatic Cancer Action Network recently announced Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. The organization also announced the 12 initial Precision Promise Clinical Trial Consortium sites selected to...
St. Jude Children’s Research Hospital and Sanger Institute, UK Agree to Full Exchange of Cancer Data
St. Jude Children’s Research Hospital and the Wellcome Trust Sanger Institute, UK, have agreed to a full exchange of cancer mutation data to support the discovery and understanding of genetic mutations causing cancers. The agreement will provide regular updates and exchanges of data between both...
What We Know and What We Need to Know About Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Ever since the landmark studies of Griffiths and colleagues in the 1970s,1 primary cytoreductive surgery followed by chemotherapy with the objective of achieving minimal residual disease has been the standard approach for women with advanced-stage epithelial ovarian cancer. However, what is...
Expert Point of View: Olivier Michielin, MS, MD, PhD
The paper’s invited discussant was Olivier Michielin, MS, MD, PhD, Head of Personalized Analytical Oncology and the Melanoma Clinic at Lausanne University Hospital in Switzerland. He called the findings of the European Organisation for Research and Treatment (EORTC) 18071 trial a “new landmark in...
Quality Science at ESMO 2016
Andrés Cervantes, MD, PhD, Scientific Chair of the 2016 European Society for Medical Oncology (ESMO) Congress, concluded the meeting earlier this month by recognizing a number of important take-home messages. At a closing press conference, Dr. Cervantes noted that the “ESMO 2016 Congress has...
Mount Sinai and Thomas Jefferson University Researchers Receive Falk Foundation Grant to Study Uveal Melanoma
Uveal melanoma is the second most common type of skin cancer. Approximately 50% of patients with uveal melanoma will develop metastasis, most commonly to the liver. The disease can appear more than 10 years after the primary lesion has been removed, lying dormant for long periods. There are...
UPMC Honors Stanley M. Marks, MD, With Endowed Chair in Hematology/Oncology Leadership
The University of Pittsburgh Medical Center (UPMC) announced that Stanley M. Marks, MD, oncologist and advocate for cancer patients throughout the western Pennsylvania region, is being honored by the UPMC and his medical partners at Oncology Hematology Association (OHA) through the establishment...
With Changing Strategies for Laryngeal Cancer, Multidisciplinary Team Approach Is Key
The treatment of cancer of the larynx has changed dramatically in recent years. With organ preservation now possible in many cases, it is more important than ever for patients to receive guidance from every corner of the field. In a recent article in the Journal of Oncology Practice (JOP),1 a...
NIH Expands National Precision Medicine Initiative Cohort Program
The National Institutes of Health (NIH) has announced awards to add four regional medical center groups to the national network of health-care provider organizations that will implement the Precision Medicine Initiative Cohort Program. Combined, the new health-care provider organizations will...
Expert Point of View: Colleen A. Lawton, MD
“This is very exciting work and is exactly what we need in prostate cancer,” said Colleen A. Lawton, MD, Vice-Chair of the Medical College of Wisconsin, Milwaukee, and moderator of a press conference where the study by Spratt et al was discussed. “The prognostic measures we use are rough and...
Expert Point of View: Vinai Gondi, MD
Formal discussant of both trials, Vinai Gondi, MD, Director of CNS Radiation Oncology at Northwestern Medicine Cancer Center in Warrenville, Illinois, offered a somewhat more nuanced take on the data from these studies. To begin, he commended the authors of both studies. “These were both...
Stereotactic Radiosurgery Achieves Better Quality of Life and Improved Cognition Than Whole-Brain Radiotherapy
Two separate randomized trials presented at the 58th Annual Meeting of the American Society of Radiation Oncology (ASTRO) affirmed the value of stereotactic radiosurgery as an option for postoperative treatment of the surgical cavity of resected brain metastases, potentially avoiding the cognitive...
Safety of Extreme Hypofractionation Reassuring in Intermediate-Risk Prostate Cancer
Giving patients larger fractions of radiation over shorter periods (ie, hypofractionation) is gaining ground in several types of cancers. This approach is attractive for patients’ convenience, shortening treatment and travel times, and also for resource utilization. Several studies have shown that ...
Retrospective Studies Confirm Survival Benefit of Stereotactic Body Radiotherapy in Early-Stage NSCLC
Stereotactic body radiation therapy is becoming more widely adopted for the treatment of early-stage non–small cell lung cancer (NSCLC). Along with its increasing uptake, survival has significantly increased over the past decade, according to two large retrospective studies presented at the 58th...
‘Dear Presidential Candidates’: A Letter From an Oncologist
Dear Presidential Candidates: Wouldn’t it be great if history’s Alexander the Great was actually Dr. Alexander Fleming, the doctor-scientist who saved millions of lives by discovering penicillin, rather than the other Alexander, who conquered and killed thousands of innocent people? Wouldn’t it be...
Study Finds Increased Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients
In the HIV-negative population, there is growing evidence suggesting that chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are both associated with the development of non-Hodgkin lymphoma (NHL), although the mechanisms underlying this association remain unclear. The incidence rate of NHL ...
Vice President Biden Delivers Cancer Moonshot Report, Announces Public and Private Sector Actions to Advance Cancer Moonshot Goals
Today in the Oval Office, Vice President Joe Biden delivered the Cancer Moonshot report to the President and the American public. The report summarizes the work of the Cancer Moonshot Task Force since its creation in January and lays out the Vice President’s strategic plan for transforming...
HHS Finalizes MACRA Rule, ASCO Applauds Focus on High-Quality Patient-Centered Care
Today, the Department of Health & Human Services (HHS) finalized a landmark new payment system for Medicare clinicians that will continue the Administration’s progress in reforming how the health-care system pays for care. The Medicare Access and CHIP Reauthorization Act of ...
Massachusetts Health Insurance Expansion Associated With Increased Resection and Reduced Emergent Resection for Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Loehrer et al found that the 2006 Massachusetts health-care reform has resulted in increased rates of resection and reduced emergent resection for colorectal cancer. The study used the Hospital Cost and Utilization Project State Inpatient...
ESMO 2016: Immunotherapy Shows Promising Results in First- and Second-Line Treatment of Metastatic Bladder Cancer in Two Trials
Immunotherapy has shown promising results in the first- and second-line treatment of metastatic bladder cancer in two phase II trials presented by Galsky et al and Balar et al at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen (Abstracts LBA31_PR and LBA32_PR,...
Characteristics of HPV-Driven Nonoropharyngeal Squamous Cell Carcinomas of the Head and Neck
In a study reported in the Journal of Clinical Oncology, Chakravarthy et al found that human papillomavirus (HPV)-driven tumors accounted for 4.1% of nonoropharyngeal squamous cell carcinomas of the head and neck. HPV-positive tumors were associated with poorer survival and reduced...
ESMO 2016: Ipilimumab as Adjuvant Therapy Improves Overall Survival in High-Risk Stage III Melanoma
Ipilimumab (Yervoy) as adjuvant therapy significantly improves overall survival in patients with high-risk stage III melanoma, according to the European Organisation for Research and Treatment of Cancer (EORTC) 18071 phase III trial results presented by Eggermont et al at the European Society for...
Lack of Androgen Receptor Protein May Contribute to Racial Disparities in Triple-Negative Breast Cancer Outcomes
Triple-negative breast cancer in African American women is much more likely to lack the androgen receptor protein compared with triple-negative breast cancer in European American women, and this may contribute to the racial disparity in survival outcomes among these two populations, according to a...
Affordable Care Act Increased Access to Cancer Care and Clinical Trial Participation Among Hispanics
Implementation of the Affordable Care Act (ACA) in California may have led to a significant increase in the number of Hispanic breast cancer patients at a National Cancer Institute (NCI)-designated cancer center and an increase in the number of Hispanic women who consented to participate in a...
Lenalidomide/Dexamethasone in High-Risk Smoldering Multiple Myeloma
Long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma, as reported by Maria-Victoria Mateos, PhD, of Instituto de Biologia...
HHS Takes Steps to Provide More Information on Clinical Trials to the Public
To make information about clinical trials widely available to the public, the U.S. Department of Health and Human Services (HHS) issued a final rule on September 19 that specifies requirements for registering certain clinical trials and submitting summary results information to ClinicalTrials.gov....
The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests
In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests being marketed as ovarian cancer screening tests” and recommended “against using currently offered tests to screen for ovarian...
The Medical Profession Has to Become Culturally Sensitive to the Needs of LGBT Cancer Survivors
Despite my breast cancer diagnosis 4 years ago, I feel really lucky. My cancer was detected relatively early, stage IIB, during a routine mammogram screening—a test that many of my lesbian friends skip because they don’t want to deal with a medical system steeped in a heterosexual culture that is...
A Space to Heal
We pass them every day on our way to the hospital, the street dwellers of our town in India. Their home consists of a plastic sheet suspended between four poles on the pavement. One day, two women sat under the plastic sheet in happy conversation. It had rained heavily the previous night, and I...
Friendship
Mr. C is almost 90 now, but every summer the boxes of squash, pumpkins, tomatoes, and other vegetables from his truck farm still arrive like clockwork at our door. The cancer that required treatment 17 years ago has never recurred. He’s now struggling with a new problem, recovering from a broken...
ASCO President-Elect Bruce E. Johnson, MD, FASCO, Reflects on Volunteer Service, Plans for Presidential Term
Bruce E. Johnson, MD, FASCO, began his term as ASCO President-Elect in June 2016 and will serve as 2017–2018 President. A thoracic cancer specialist, Dr. Johnson is Chief Clinical Research Officer and institute physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical...
Bishoy Faltas, MD, Joins Weill Cornell Medicine Hematology and Medical Oncology
On July 1, 2016, Bishoy Faltas, MD, joined the Genitourinary Oncology Program in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. As a laboratory-based physician-scientist, Dr. Faltas will focus on studying mechanisms of mutagenesis and drug resistance in bladder...
Eric Fearon, MD, PhD, Named Director of University of Michigan Comprehensive Cancer Center
Eric Fearon, MD, PhD, has been named Director of the University of Michigan Comprehensive Cancer Center. Dr. Fearon, the Emanuel N. Maisel Professor of Oncology at the University of Michigan, is a nationally recognized investigator in cancer genetics. His research has led to a greater...
Susan M. O’Brien, MD, Embraces the Challenge of Balancing Patient Care With Clinical Trial Investigation
Susan M. O’Brien, MD, one of the nation’s foremost leukemia experts, told The ASCO Post that she wanted to become a doctor since her earliest memories. “The idea of being able to help sick people always appealed to me,” said Dr. O’Brien, who was born in Manhattan but spent her formative years in...
Some Gains Reported in Enrollment Disparity in National Lung Cancer Trials
Pang et al found that the enrollment disparity in clinical trials in lung cancer has been reduced in recent years for older patients and women overall, according to a study reported in the Journal of Clinical Oncology. However, disparities persist for elderly women, blacks, Asian/Pacific Islanders, ...
Small Cell Lung Cancer and Immunotherapy: A Change Is Coming, Just Not Front Line (Yet!)
Ever since the immune checkpoint agents arrived, the pace of clinical investigation in oncology has continued to accelerate with an ever-increasing number of trials of single-agent and combination therapies with novel designs that are transforming our drug-development process. However, even in...
John Karanicolas, PhD, Joins the Fox Chase Cancer Center Molecular Therapeutics Program
John Karanicolas, PhD, has joined the Fox Chase Cancer Center as Associate Professor in the Molecular Therapeutics Program. Dr. Karanicolas, a computational chemist, earned his doctorate from the Scripps Research Institute. He completed his postdoctoral fellowship at the University of Washington....
Friends of Cancer Research Honors Oncology Leaders at 20th Anniversary and Announces Partnership
Friends of Cancer Research (Friends) celebrated its 20th anniversary September 21 at a special event in Washington, DC. The event honored Janet Woodcock, MD; Eric Lander, PhD; and Sean Parker. Dr. Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug...
Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer
Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...
Susan G. Komen Announces $27 Million Initiative to Reduce Breast Cancer Deaths in African American Community
The Susan G. Komen breast cancer organization gathered philanthropic, civic, medical, and business leaders in Washington, DC, September 14 to formally launch a $27 million, 10-city initiative to reduce breast cancer death rates among African American women. “African American women are almost 40%...
Oncology Researchers, Clinicians Selected as Endocrine Society 2017 Laureate Award Winners
The Endocrine Society selected 14 leaders in the endocrinology field as winners of the organization’s prestigious 2017 Laureate Awards. Established in 1944, the Laureate Awards recognize the highest achievements in the endocrinology field. Three oncology leaders in particular were recognized for...
Jacques Galipeau, MD, FRCP(C), Brings Personalized Stem Cell Treatment to UW Carbone
An international leader in harnessing a patient’s own stem cells to fight cancer and autoimmune diseases joined the faculty of the University of Wisconsin (UW) Carbone Cancer Center on September 1. Jacques Galipeau, MD, FRCP(C), came from the Winship Cancer Center at Emory University, where he...
Benefits of Early Palliative Care Interventions Extend Beyond the Patient
A session at the 2016 Palliative Care in Oncology Symposium focused on the special needs of cancer caregivers. In a large survey, caregivers of persons with cancer reported higher levels of stress and significantly more duties than caregivers of other patients. But, according to research from...
